<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since 1975, <z:hpo ids='HP_0000001'>all</z:hpo> histologic subtypes of Stage III and IIIE nodular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients were treated with a combination of radiotherapy and multiple-agent chemotherapy consisting of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="8382">prednisone</z:chebi>, and <z:chebi fb="0" ids="3139">bleomycin</z:chebi> (CHOP-Bleo) </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty-eight patients were treated through 1979 </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment consisted of two cycles of CHOP-Bleo alternating with sequential radiotherapy to clinically involved regions, and further CHOP-Bleo to a total of ten cycles </plain></SENT>
<SENT sid="3" pm="."><plain>Radiotherapy doses ranged between 3000 and 4000 rad delivered in three to four weeks </plain></SENT>
<SENT sid="4" pm="."><plain>Forty-six patients completed treatment </plain></SENT>
<SENT sid="5" pm="."><plain>In the other 12 patients, treatment was interrupted because of progressive disease in seven, and <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> in five </plain></SENT>
<SENT sid="6" pm="."><plain>Overall five-year survival and disease-free survival results were 82% and 47%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Survival for those patients who completed therapy was 93% </plain></SENT>
<SENT sid="8" pm="."><plain>By histopathology, survivals for <z:hpo ids='HP_0000001'>all</z:hpo> patients were: poorly differentiated lymphocytic, 100%; mixed cell, 80%; and histiocytic, 39% </plain></SENT>
<SENT sid="9" pm="."><plain>Disease-free figures for <z:hpo ids='HP_0000001'>all</z:hpo> 58 patients were: poorly differentiated lymphocytic, 44%; mixed cell, 65%; and histiocytic, 35% </plain></SENT>
<SENT sid="10" pm="."><plain>The extent of abdominal disease influenced five-year survival as follows: 100% for those who had only occult disease at staging laparotomy; 88% for those who were Stage III on the basis of a positive lymphangiogram; and 50% for those who had a palpable mass or required an exploratory laparotomy for symptoms </plain></SENT>
<SENT sid="11" pm="."><plain>Five of seven patients with progression during protocol therapy have died </plain></SENT>
<SENT sid="12" pm="."><plain>No patients died as a result of <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>A number of patients developed complications during treatment, none of which were fatal </plain></SENT>
<SENT sid="14" pm="."><plain>Eight patients developed <z:e sem="disease" ids="C0019360" disease_type="Disease or Syndrome" abbrv="ZONA">herpes zoster</z:e>, four patients developed transient radiation <z:hpo ids='HP_0012115'>hepatitis</z:hpo>, and four patients had miscellaneous complications </plain></SENT>
</text></document>